<SEC-DOCUMENT>0001104659-20-108972.txt : 20201026
<SEC-HEADER>0001104659-20-108972.hdr.sgml : 20201026
<ACCEPTANCE-DATETIME>20200925170749
ACCESSION NUMBER:		0001104659-20-108972
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200923
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200925
DATE AS OF CHANGE:		20200925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		201200885

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2489609009

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2031704-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:rmti="http://rockwellmed.com/20200923">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_rmti_rockwellmed.com_20200923 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20200923_20200923_zeh8l20n4hrc -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001041024 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityCentralIndexKey">0001041024</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="rmti-20200923.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-09-23to2020-09-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-23</xbrli:startDate>
        <xbrli:endDate>2020-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_902_edei--DocumentType_c20200923__20200923_zqwh1gGgGYL6"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <b>September 25</b> <b>&#160;(<span id="xdx_905_edei--DocumentPeriodEndDate_c20200923__20200923_zVlMgY9wrbfb"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September
23, 2020</ix:nonNumeric></span></b><b>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityRegistrantName_c20200923__20200923_zGTNdJgnTOX4"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityRegistrantName">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20200923__20200923_ziLbrSGINLk9"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityFileNumber_c20200923__20200923_zRV7Xe1zuAXb"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityFileNumber">000-23661</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20200923__20200923_zewK5S9TTYB1"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityTaxIdentificationNumber">38-3317208</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.5pt; vertical-align: top; text-align: center">(State or other jurisdiction <br />
of incorporation)</td>
    <td style="padding: 1.5pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="padding: 1.5pt; vertical-align: top; text-align: center">(IRS Employer<br />
 Identification No.)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20200923__20200923_zlLFSwBTuNd7"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityAddressAddressLine1">411 Hackensack Avenue</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20200923__20200923_zuO7LzLJv91b"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityAddressAddressLine2">Suite&#160;501</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressCityOrTown_c20200923__20200923_zmS4iLiAZn65"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityAddressCityOrTown">Hackensack</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20200923__20200923_zYXlYTCJhVB2"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20200923__20200923_zJYSfJVsw6Ga"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:EntityAddressPostalZipCode">07601</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90E_edei--CityAreaCode_c20200923__20200923_z2vqKK6GPOil"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:CityAreaCode">248</ix:nonNumeric></span>)<span id="xdx_903_edei--LocalPhoneNumber_c20200923__20200923_zCZF6pK3o9Yg"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:LocalPhoneNumber">960-9009</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.125in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20200923__20200923_zbjw5DlH1Xzd"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.125in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--SolicitingMaterial_c20200923__20200923_zS7pneqRziKl"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.125in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20200923__20200923_zMTSTMhyhS55"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.125in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20200923__20200923_zY6qA7NnYnTb"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Title&#160;of&#160;Each&#160;Class</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Trading&#160;Symbol</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-left: 1.5pt">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_909_edei--Security12bTitle_c20200923__20200923_z1RWPCSwNnxh"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_908_edei--TradingSymbol_c20200923__20200923_z4HeFAk3gfpe"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" name="dei:TradingSymbol">RMTI</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_905_edei--SecurityExchangeName_c20200923__20200923_zxn1pCBI0Yx6"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Market</ix:nonNumeric></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20200923__20200923_zZFuVlDqir98"><ix:nonNumeric contextRef="From2020-09-23to2020-09-23" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.
</span><span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Item 1.01</span></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><span style="text-decoration: underline">Entry
into a Material Definitive Agreement</span>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 23, 2020, Rockwell Medical, Inc., a Delaware corporation
(the &#8220;Company&#8221;), entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering
(the &#8220;Offering&#8221;), 21,818,544 shares of its common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;),
and warrants to purchase up to 23,178,809 shares of its Common Stock (the &#8220;Warrants&#8221;) at a combined purchase price
equal to $1.51 per share and associated warrant to several institutional and accredited investors. Each Warrant is exercisable
for one share of the Company&#8217;s Common Stock at an exercise price of $1.80 per share. The Warrants are immediately exercisable
and will expire 24 months from the issue date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also offered to certain purchasers pre-funded warrants
to purchase up to an aggregate of 1,360,265 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of
Common Stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of Common Stock is sold to the
public in this offering, minus $0.001, and the exercise price of each pre Pre-Funded Warrant is $0.001 per share. The Company received
gross proceeds of approximately $35.0 million in connection with the Offering, before deducting placement agent fees and related
offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A holder (together with its affiliates) may not exercise any
portion of the Warrant to the extent that the holder would own more than 9.99% (or, at the holder&#8217;s option upon issuance,
4.99%) of the Company&#8217;s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in
accordance with the terms of the Warrant or Pre-Funded Warrant. The Purchase Agreement contains customary representations and warranties
and agreements of the Company and the Purchasers and customary indemnification rights and obligations of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to a letter agreement, dated September 22, 2020, as
amended on September 22, 2020 (the &#8220;Engagement Letter&#8221;), the Company engaged H.C. Wainwright &amp; Co., LLC as its
exclusive placement agent (the &#8220;Placement Agent&#8221;) in connection with the Offering. The Placement Agent agreed to use
its reasonable best efforts to arrange for the sale of the securities in the Offering. The Company agreed to pay to the Placement
Agent a cash fee of 6.0% of the aggregate gross proceeds raised in the Offering, minus $420,000 payable by the Company to a financial
advisory firm for services related to this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company agreed to pay
the Placement Agent (i) 6.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any warrants issued
to investors the Purchasers in the Offering from the exercise of warrants during the fifteen (15) months period commencing on the
issuance date and (ii) 4.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any warrants issued
in the Offering from the exercise of warrants during the remainder term of such warrants. The Company has also agreed to pay the
Placement Agent non-accountable expenses of $50,000 as well as $12,900 for the clearing fees of the Placement Agent in connection
with this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also agreed to pay the placement
agent, subject to certain exceptions, a tail fee equal to the cash and warrant compensation in this Offering, if any investor who
was contacted or introduced to the Company by the Placement Agent during the term of its engagement or introduced to the Company
by the Placement Agent during the term of its engagement, provides the Company with capital in any public or private offering or
other financing or capital raising transaction during the 6-month period following the termination or expiration of the Engagement
Letter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing summaries of the Purchase Agreement, the Warrants,
and the Pre-Funded Warrants do not purport to be complete and are subject to, and qualified in their entirety by, the forms of
such documents attached as Exhibits 10.1, 4.1, and 4.2, respectively, to this Current Report on Form 8-K, which are incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares of Common Stock, the Warrants, the Pre-Funded Warrants
and the shares of Common Stock issuable thereunder, were offered by the Company pursuant to a registration statement on Form S-3
(File No. 333- 227363), which was filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on September
14, 2018 and was declared effective by the Commission on October 1, 2018 (the &#8220;Registration Statement&#8221;). A copy of
the opinion of Gibson, Dunn &amp; Crutcher LLP relating to the legality of the issuance and sale of the Securities in the Offering
is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K shall not constitute an offer
to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Item
9.01</span></b></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b><span style="text-decoration: underline">Financial Statements and Exhibits</span>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(d)&#160;<i>Exhibits</i>.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;
The following exhibit is being filed herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">EXHIBIT&#160;INDEX</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 88%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr>
    <td style="vertical-align: top"><a href="tm2031704d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2031704d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Warrant</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="tm2031704d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2031704d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Pre-Funded Warrant</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="tm2031704d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2031704d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Opinion of Gibson, Dunn &amp; Crutcher LLP</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="tm2031704d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2031704d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Securities
Purchase Agreement dated September 23, 2020</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="tm2031704d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2031704d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit 5.1)</span></a></td></tr>
<tr>
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline">SIGNATURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>ROCKWELL MEDICAL,&#160;INC.</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Date: September 25, 2020</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Russell Ellison</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Russell Ellison</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi05/dNGdFhWxihQRt0ObymA7KZnx70je0rFFDIGQvPflCTESa1rpBhnOiyKHI7ZdoxxCgTUymhK9I9tsU/CzwIu2jpVx/foDM/IMemY6jkt/7513bbFKQc4mMplEEmSSxiHMdyL46hmZWldonFYNKFPBgaljjU7xa/hwVE8y1L76pBOy1WRSCMdykN8QyTCCPd3Vg/hqIc8zEYz6CsSa6dZ9Y27WUQvLBlufZQf038EH0vxJBg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2031704d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>FORM OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Rockwell
Medical,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif">Warrant Shares: _______&nbsp;</TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">Issue Date:______, 2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Initial Exercise Date: _______,
2020</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New York
City time) on ______________<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT> (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Rockwell Medical,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of the Company&rsquo;s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;1</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September&nbsp;23, 2020, among the Company and the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;2</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire
transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> The date that is 24 months from the Initial Exercise
Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.80, subject to adjustment hereunder (the
 &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may only be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD>
    <TD STYLE="width: 0.1in">= </TD><TD STYLE="text-align: justify">as applicable: (i)&nbsp;the VWAP on the Trading Day
immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant
to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule&nbsp;600(b)(68)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either
(y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price
of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading
Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR>                                   <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">(B)</TD>
    <TD>=</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">(X)</TD>
    <TD>=</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the
Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is
not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is
not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of
the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting
the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised
via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in
the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise
to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (A)&nbsp;the earlier of (i)&nbsp;two
(2)&nbsp;Trading Days and (ii)&nbsp;the number of days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise and (B)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to
the Company (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2)&nbsp;Trading
Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.
If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the
date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered
on or prior to 4:00 p.m.&nbsp;(New York City time) on the Trading Date prior to the Initial Exercise Date, which may be delivered
at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to
such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be
the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the
case of a cashless exercise) is received by such Warrant Share Delivery Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares on a timely basis pursuant
to Section&nbsp;2(d)(i)&nbsp;by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section&nbsp;2(d)(i)&nbsp;above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date
the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to
the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price
at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the
Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and
all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and
the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act
and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public
announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number
of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%]
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (and
all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct
or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to
which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and
has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of
this Warrant) and the Company shall cause the successor or acquiring corporation to assume such obligations, including the obligation
to pay the Alternate Consideration upon any exercise of this Warrant. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to
the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock
is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver
such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;4</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in
such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue
Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;5</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except
as expressly set forth in Section&nbsp;3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise,&rdquo; and to receive the cash payments contemplated pursuant to Sections 2(d)(i)&nbsp;and 2(d)(iv), in no event will
the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from
any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that the
right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>Rockwell Medical,&nbsp;Inc.</B></FONT> &nbsp; &nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 47%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>Name: </TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>Title: &nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Rockwell
Medical,&nbsp;Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT> <FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT> <FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT> <FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 36%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 64%"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 79%"> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 79%"> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>(Please Print) </TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">Phone Number:</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">Email Address:</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify; width: 15%"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: justify; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>tm2031704d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Rockwell
Medical,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 70%; text-align: left"><FONT STYLE="font-size: 10pt">Warrant Shares:____________________</FONT></TD><TD STYLE="text-align: justify; width: 30%">Issue
Date:__________, 2020</TD>
</TR>                                   <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Initial Exercise Date: _________,
2020</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON
STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
 &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant
is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Rockwell
Medical,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;1</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September&nbsp;23, 2020, among the Company and the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;2</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire
transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was
pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than
the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any
exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate
exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised
prior to the Termination Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001,
subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD>
    <TD STYLE="width: 0.25in">&nbsp;=</TD><TD STYLE="text-align: justify">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such
Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading
Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of
 &ldquo;regular trading hours&rdquo; (as defined in Rule&nbsp;600(b)(68) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as
reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter
(including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof
or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day
and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left">(B)</TD>
    <TD STYLE="width: 0.25in">&nbsp;=</TD>
    <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left">(X)</TD>
    <TD STYLE="width: 0.25in">&nbsp;=</TD>
    <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the
Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is
not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is
not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of
the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary: (a)&nbsp;on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section&nbsp;2(c), and (b)&nbsp;in the event that the Registration Statement is not current and effective at the
time of exercise of this Warrant, then it shall only be exercisable on a cashless basis in accordance with this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to
or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise
by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee,
for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earlier of (A)&nbsp;the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the
number of days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise
and (B)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of
the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a
cashless exercise) is received within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days
comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to
deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
 &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on
the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice
of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New
York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement,
the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Initial
Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares on a timely basis pursuant
to Section&nbsp;2(d)(i)&nbsp;by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section&nbsp;2(d)(i)&nbsp;above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date
the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash
to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of
Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the
price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the
Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and
all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and
the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act
and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public
announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number
of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%]
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;3</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (and
all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct
or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to
which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and
has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of
this Warrant) and the Company shall cause the successor or acquiring corporation to assume such obligations, including the obligation
to pay the Alternate Consideration upon any exercise of this Warrant. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to
the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause
to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the
Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;4</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;5</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except
as expressly set forth in Section&nbsp;3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise,&rdquo; and to receive the cash payments contemplated pursuant to Sections 2(d)(i)&nbsp;and 2(d)(iv), in no event will
the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from
any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that the
right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Rockwell Medical,&nbsp;Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Rockwell
Medical,&nbsp;Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT>&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 82%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 64%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 79%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 79%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 96%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _____________________ __, ______</FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 13%"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 36%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 49%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2031704d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2031704d1_ex5-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 25, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical, Inc.<BR>
411 Hackensack Avenue, Suite 501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hackensack, New Jersey 07601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in">Re:</TD><TD><I>Rockwell Medical Inc.<BR>
Registration Statement on Form&nbsp;S-3 (File No. 333-227363)</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To Whom it May Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have examined the Registration Statement on Form S-3, as
amended (the &ldquo;<U>Registration Statement</U>&rdquo;), of Rockwell Medical, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;)
filed pursuant to the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), in connection with the offering
by the Company of (a) 21,818,544 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.0001
per share (the &ldquo;<U>Common Stock</U>&rdquo;) (b) 1,360,265 pre-funded Common Stock purchase warrants (the &ldquo;<U>Pre-Funded
Warrants</U>&rdquo;) to purchase up to 1,360,265 shares of Common Stock (the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;) and
(c) 23,178,809 Common Stock purchase warrants (the &ldquo;<U>Warrants</U>&rdquo;) to purchase up to 23,178,809 shares of Common
Stock (the &ldquo;<U>Warrant Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In arriving at the opinions expressed below, we have examined
originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals,
of specimen common stock certificates, and such other documents, corporate records, certificates of officers of the Company and
of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth
below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity
and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original
documents of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing, and subject to the assumptions, exceptions,
qualifications and limitations set forth herein, we are of the opinion that: (i) the Shares, when issued against payment therefor
as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable; (ii) the Warrant Shares, when
issued upon exercise of the Warrants, will be validly issued, fully paid and non-assessable; (iii) the Pre-Funded Warrant Shares,
when issued upon exercise of the Pre-Funded Warrants against payment therefor as set forth in the Registration Statement, will
be validly issued, fully paid and non-assessable; and (iv) the Warrants and the Pre-Funded Warrants when issued as set forth in
the Registration Statement, will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2031704d1_ex5-1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 25, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opinions expressed above are subject to the following additional
exceptions, qualifications, limitations and assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. We render no opinion herein as to matters involving the laws
of any jurisdiction other than the State of New York and the United States of America and, for purposes of clauses (i), (ii) and
(iii), the Delaware General Corporation Law. We are not admitted to practice in the State of Delaware; however, we are generally
familiar with the Delaware General Corporation Law as currently in effect and have made such inquiries as we consider necessary
to render the opinions contained in clauses (i), (ii) and (iii) above. This opinion is limited to the effect of the current state
of the laws of the State of New York, the United States of America and, to the limited extent set forth above, the laws of the
State of Delaware and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event
of future changes in such laws or the interpretations thereof or such facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. The opinion in clause (iv) above is subject to (a) the effect
of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors&rsquo;
generally, including without limitation the effect of statutory or other laws regarding fraudulent transfers or preferential transfers,
and (b) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair
dealing and the possible unavailability of specific performance, liquidated damages, injunctive relief or other equitable remedies
regardless of whether enforceability is considered in a proceeding in equity or at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the filing of this opinion as an exhibit to the
Registration Statement, and we further consent to the use of our name under the caption &ldquo;Legal Matters&rdquo; in the Registration
Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the
category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Gibson, Dunn &amp; Crutcher, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>tm2031704d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of September&nbsp;23, 2020, between Rockwell Medical,&nbsp;Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each,
including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&nbsp;IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><U>&ldquo;Class&nbsp;A
Units</U>&rdquo; means each Class&nbsp;A unit consisting of (a)&nbsp;one Share, and (b)&nbsp;one Series&nbsp;A Warrant to purchase
one (1)&nbsp;Series&nbsp;A Warrant Share(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class&nbsp;A
Unit Purchase Price</U>&rdquo; equals $1.51 per each Class&nbsp;A Unit, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement
and prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class&nbsp;B
Units</U>&rdquo; means each Class&nbsp;B unit consisting of (a)&nbsp;one Pre-Funded Warrant to initially purchase one Pre-Funded
Warrant Share, and (b)&nbsp;one Series&nbsp;A Warrant to purchase one (1)&nbsp;Series&nbsp;A Warrant Share(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class&nbsp;B
Unit Purchase Price</U>&rdquo; equals $1.509 per each Class&nbsp;B Unit, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement
and prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and
(ii)&nbsp;the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event
later than the second (2nd) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Company Counsel</U>&rdquo;
means Gibson, Dunn&nbsp;&amp; Crutcher LLP, with offices located at 555 Mission Street, Suite&nbsp;3000, San Francisco, California
94105.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York
City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day
immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if
this Agreement is signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later
than 9:01 a.m.&nbsp;(New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers or directors of the
Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board
of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other
securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with
stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are
issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein,
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall
provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright&nbsp;&amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a)&nbsp;hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire
when exercised in full, in the form of <U>Exhibit&nbsp;A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is
filed with the Commission and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No.&nbsp;333-227363 which registers the sale
of the Shares, the Warrants and the Warrant Shares to the Purchasers, including all information, documents and exhibits filed with
or incorporated by reference into such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted
from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted
from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Units, the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;A
Warrants</U>&rdquo; means, collectively, the Series&nbsp;A Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a)&nbsp;hereof, which Series&nbsp;A Warrants shall be exercisable immediately upon issuance
and have a term of exercise equal to 24 months following the initial exercise date, in the form of <U>Exhibit&nbsp;A-1</U> attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;A
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Series&nbsp;A Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but
shall not be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Class&nbsp;A Units and/or Class&nbsp;B Units
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the
heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, the current transfer agent of the Company, with a mailing
address of 6201 15th Ave, Brooklyn, New York 11219, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Units</U>&rdquo;
means, collectively, the Class&nbsp;A Units and the Class&nbsp;B Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Series&nbsp;A Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Series&nbsp;A Warrant Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an aggregate of approximately $35.0 million of Class&nbsp;A Units as determined
pursuant to Section&nbsp;2.2(a); provided, however, that, to the extent that a Purchaser determines, in its sole discretion, that
such Purchaser (together with such Purchaser&rsquo;s Affiliates, and any Person acting as a group together with such purchaser
or any of such Purchaser&rsquo;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as such
Purchaser may otherwise choose, in lieu of purchasing Class&nbsp;A Units such Purchaser may elect to purchase Class&nbsp;B Units
at the Class&nbsp;B Unit Purchase Price in lieu of Class&nbsp;A Units in such manner to result in the same aggregate purchase price
being paid by such Purchaser to the Company. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 9.99% (or, at the election
of the Purchaser, 4.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of the Securities on the Closing Date. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page&nbsp;hereto
executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement
with the Company or its designees. The Company shall deliver to each Purchaser its respective Shares or Pre-Funded Warrants (as
applicable to such Purchaser) and Series&nbsp;A Warrants as determined pursuant to Section&nbsp;2.2(a), and the Company and each
Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the covenants
and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of the Placement Agent or such other location
as the parties shall mutually agree. The Company covenants that, if the Purchaser delivers a Notice of Exercise (as defined in
the Pre-Funded Warrant) no later than 12:00 p.m.&nbsp;(New York City time) on the Closing Date to exercise any Pre-Funded Warrants
between the date hereof and the Closing Date, the Company shall deliver Pre-Funded Warrant Shares to the Purchaser on the Closing
Date in connection with such Notice of Exercise. Unless otherwise directed by the Placement Agent, settlement of the Shares shall
occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses
and released by the Transfer Agent directly to the account(s)&nbsp;at the Placement Agent identified by each Purchaser; upon receipt
of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment
therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the
Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">subject
to the last sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Class&nbsp;A Units divided by the Class&nbsp;A
Unit Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">for
each Purchaser of Class&nbsp;B Units, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Class&nbsp;B Units divided
by the Class&nbsp;B Unit Purchase Price, with an exercise price equal to $0.001, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Series&nbsp;A Warrant registered in the name of each such Purchaser to purchase up to a number of shares of Common Stock equal
to 100% of the aggregate number of Shares and the Pre-Funded Warrant Shares underlying the Pre-Funded Warrants initially issuable
on the date hereof, if any, purchased by such Purchaser with an exercise price equal to $1.80, subject to adjustment therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount with regard to the Pre-Funded Warrants purchased by such Purchaser, if any, by wire transfer
to the account specified by the Company in Section&nbsp;2.2(a)(iii)&nbsp;above, or as otherwise agreed by the Company and the Placement
Agent; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount with regard to the Shares purchased by such Purchaser, which shall be made available for
DVP settlement with the Company or its designees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules or in the SEC Reports, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties
to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i)&nbsp;a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii)&nbsp;a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material
adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii)&nbsp;or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith
or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar
as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s
certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien
upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment,
anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which
the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected,
or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the
filings required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus Supplement,
(iii)&nbsp;application(s)&nbsp;to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon
in the time and manner required thereby, and (iv)&nbsp;such filings as are required to be made under applicable state securities
laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration
Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;October&nbsp;1, 2018 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Company was at the time of the filing of the Registration Statement eligible to use Form&nbsp;S-3. The Company
is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the transaction requirements as set forth in General Instruction
I.B.1 of Form&nbsp;S-3. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending
the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus or the Prospectus Supplement
has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company,
are threatened by the Commission. The Company, if required by the rules&nbsp;and regulations of the Commission, shall file the
Prospectus Supplement with the Commission pursuant to Rule&nbsp;424(b). At the time the Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
and the Prospectus Supplement or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform
in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g</U>), which <U>Schedule 3.1(g)</U>&nbsp;shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date
hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other
than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person
has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights
or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by
which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents
or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to
issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities
or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price
of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security
of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans
or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none
of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale
of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s
stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on
a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject
to Rule&nbsp;144(i)&nbsp;under the Securities Act. The financial statements of the Company included in the SEC Reports comply in
all material respects with applicable accounting requirements and the rules&nbsp;and regulations of the Commission with respect
thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as
may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may
not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then
ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i)&nbsp;there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred
any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial
statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method
of accounting, (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders
or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has
not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans.
The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance
of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has
not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or
the Securities or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any
Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange
Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not
been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of
any court, arbitrator or other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to
taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except
in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>.</FONT>&nbsp;<FONT STYLE="font-size: 10pt">The Company and its Subsidiaries (i)&nbsp;are
in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment
(including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans
or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each
clause (i), (ii)&nbsp;and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and
(ii)&nbsp;Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years
from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial
statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property
Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material
Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure
to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has
no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights.
The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property
Rights that are necessary to conduct its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transactions
With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement
for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under
any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of
the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the
Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv)&nbsp;the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and
15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The Company&rsquo;s certifying
officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the
end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in
this Section&nbsp;that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject
to registration under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible
for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the
Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this
Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3.2
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets
exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company
would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the
Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (y)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required
to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and
local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it
is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for
the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made
any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or
made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any
material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is Marcum LLP. To the knowledge and belief of the Company, such
accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its
opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending
December&nbsp;31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents
to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been
based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(e)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the
Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or
short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold
the Securities for any specified term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future
private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any
Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly,
presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have
any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company
further understands and acknowledges that (y)&nbsp;one or more Purchasers may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant
Shares deliverable with respect to Securities are being determined, and (z)&nbsp;such hedging activities (if any) could reduce
the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are
being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid
to the Company&rsquo;s placement agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules&nbsp;and regulations relating
to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good
laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports,
except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the
Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)&nbsp;contests
the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)&nbsp;withdraws its approval
of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold on any clinical investigation by the Company or any
of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company or any of its Subsidiaries, (v)&nbsp;enters or
proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&nbsp;otherwise
alleges any violation of any laws, rules&nbsp;or regulations by the Company or any of its Subsidiaries, and which, either individually
or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and
are being conducted in all material respects in accordance with all applicable laws, rules&nbsp;and regulations of the FDA.&nbsp;
The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States
of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)&nbsp;in
accordance with the terms of the Company&rsquo;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there
is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding the Company or its
Subsidiaries or their financial results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System
(the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar
as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise
in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary
course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercises any Warrants, it will be either: (i)&nbsp;an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1),
(a)(2), (a)(3), (a)(7)&nbsp;or (a)(8)&nbsp;under the Securities Act or (ii)&nbsp;a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule&nbsp;144A(a)&nbsp;under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as
it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of
the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses
or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to
the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement
Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice
necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company
or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect
to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities
to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such
Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales
or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company acknowledges
and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Warrant
Shares. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the
issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant
to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise
available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing
that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration
statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the
foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance
with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including
the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>. Until the earlier of the time that (i)&nbsp;no Purchaser owns Securities and (ii)&nbsp;the Warrants have expired,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all
reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then
subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules&nbsp;and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press
release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered
to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or
agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company
and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated
hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement
without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each
Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except
if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection with the filing
of final Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause
(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the
Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented
to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.
To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent,
the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of
its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any
of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any
portion of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business
and prior practices), (b)&nbsp;for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement
of any outstanding litigation or (d)&nbsp;in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against
the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is
not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party
in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the
extent that (x)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company has
failed after a reasonable period of time to assume such defense and to employ counsel or (z)&nbsp;in such action there is, in the
reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of
such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1)&nbsp;for any settlement by a Purchaser
Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to
the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach
of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnification required by this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any
liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on
the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote
all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares
on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading
Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary
to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The
Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market
and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of
the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section&nbsp;4.12 shall not apply in respect of an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as
a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section&nbsp;4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until
such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press
release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this
transaction and the information included in the Disclosure Schedules.&nbsp; Notwithstanding the foregoing, and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the
Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.4, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no
Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries
after the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp; Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Capital
Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split
or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of
the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be
required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares
in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company
and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages&nbsp;attached
hereto at or prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission,
if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as
set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York
City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the sum of (i)&nbsp;the
Shares and (ii)&nbsp;the Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants based on the initial
Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision
is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group
of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations
of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent
of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each
Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is
intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8, Section&nbsp;4.16
and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section&nbsp;4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such
rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for
such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through the legal counsel of the Placement Agent.
The legal counsel of the Placement Agent does not represent any of the Purchasers and only represents the Placement Agent. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company
and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and
not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U></FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If the last or appointed
day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such
action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment
for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that
occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.21</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Rockwell
Medical,&nbsp;Inc.</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Russell H. Ellison
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">E-mail:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">Name: Russell H. Ellison
</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: President &amp; CEO</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bodman, PLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">201 W. Big Beaver Road, Suite 500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Troy, MI 48084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Michael Costello</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gibson, Dunn &amp; Crutcher, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">555 Mission Street,
Suite 3000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Francisco, CA 94941</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Ryan A. Murr</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO RMTI SECURITIES
PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Name of Purchaser:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 35%">Signature of Authorized Signatory of Purchaser:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Name of Authorized Signatory:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Title of Authorized Signatory:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Email Address of Authorized Signatory:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Facsimile Number of Authorized Signatory:</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">Address for Notice to Purchaser:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Address for Delivery of Securities to Purchaser (if not same as address for notice):</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Class&nbsp;A Units: &nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Shares: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Series&nbsp;A Warrant Shares: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">&#168;</FONT>4.99% or <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>
9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Class&nbsp;B Units: _______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pre-Funded Warrants:_________________ Beneficial
Ownership Blocker <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT> 4.99% or <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Series&nbsp;A Warrant Shares: ______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Wingdings"> </FONT>Notwithstanding
anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be
disregarded, (ii) the Closing shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii) any
condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required
delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as
applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the
above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable)
to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>









</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>rmti-20200923.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaOHubPtzp5xWekhuWhxbTmqzyctDITN5iCKsy2G4WoL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:rmti="http://rockwellmed.com/20200923" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20200923">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://rockwellmed.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rmti-20200923_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rmti-20200923_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>rmti-20200923_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>rmti-20200923_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:href="rmti-20200923.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://rockwellmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2031704d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2031704d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A N # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>%S9Q%H<;&(R1@[A]<'D>AYH RM#N+Q[NREGO9IUU&S>Z:*0+M@8-'A4P <
M28YS]T=\YZ.JMOIUG:3236]M''))G<RCKDY/TYY^M6J "BBB@ HHHH ****
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MUJ'5=?U![+4+&6\LK>2&WG8R&-E,^URF(QO^4CY<G+<NM=H;2V,S2FWB\Q@
MS[!D@'(!/L:26RM)]OG6L,FUBR[XP<$]2,]Z .:N_%%U'LB@-KY[O<+M8$X"
M7<<"D@,#T<D^X[56N?$VL07;VX:R/V>UN[B9C W[SR9$4!1O^7(<Y//(KK18
MVBS23+:P"60Y=Q&-S'CJ>_0?E3S;0%BQAC)(*DE!R#U'XX% &/J.M^5>P1VU
M[91PA97FDF^8$QNB,@((PV7([X..*S3XCU)Y'CB>SWR3I&O[ICY -PT1#C=\
MQ^4XZ<JU=2UG;.4+6T+%',BY0':_]X>A]Z%M+='=UMX@TC!W(099AT)]3[T
M8V@:IJ%[)&M\]NXFM$N%\F(IM))!'+'/;TK?IBQ1IC9&JX&T8&,#TI] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2031704d1_ex5-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2031704d1_ex5-1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J E4# 2(  A$! Q$!_\0
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MKC8P4D?> ;&TD=P#D=ZO5R+VNKVVKS-IMA-$K2S22J\ZFVF!1BK+SO1R^W.
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GC0(BJJC@*HP!3J** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2031704-1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20200923.xsd" xlink:type="simple"/>
    <context id="From2020-09-23to2020-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-09-23</startDate>
            <endDate>2020-09-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-09-23to2020-09-23">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-09-23to2020-09-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-09-23to2020-09-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-09-23to2020-09-23">2020-09-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-09-23to2020-09-23">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-09-23to2020-09-23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-09-23to2020-09-23">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-09-23to2020-09-23">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-09-23to2020-09-23">411 Hackensack Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-09-23to2020-09-23">Suite&#160;501</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-09-23to2020-09-23">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-09-23to2020-09-23">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-09-23to2020-09-23">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-09-23to2020-09-23">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-09-23to2020-09-23">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-09-23to2020-09-23">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-09-23to2020-09-23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-09-23to2020-09-23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-09-23to2020-09-23">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-09-23to2020-09-23">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-09-23to2020-09-23">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-09-23to2020-09-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-09-23to2020-09-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139926187697960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 23,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">411 Hackensack Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MOKZ&A@\2SULRIWO\&6HQJ#=;U6-8EZ5JCS^%]RBYGQON_Q+%#U!+ P04
M" #XB#E1EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M" #XB#E1)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ ^(@Y4660>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    " #XB#E1!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /B(.5%Z
M%$.D[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( /B(.5&97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ^(@Y4=4+Y[9,!
MV!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( /B(.5&#J:4#U $  #(&   -              "  9 ,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ ^(@Y49>*NQS     $P(   L
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64$L%!@     )  D /@(   <3

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2031704-1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2031704-1_8k.htm">tm2031704-1_8k.htm</File>
    <File>rmti-20200923.xsd</File>
    <File>rmti-20200923_lab.xml</File>
    <File>rmti-20200923_pre.xml</File>
    <File>tm2031704d1_ex10-1.htm</File>
    <File>tm2031704d1_ex4-1.htm</File>
    <File>tm2031704d1_ex4-2.htm</File>
    <File>tm2031704d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2031704-1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2031704-1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20200923_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20200923_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20200923.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20200923",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2031704-1_8k.htm",
      "contextRef": "From2020-09-23to2020-09-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://rockwellmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2031704-1_8k.htm",
      "contextRef": "From2020-09-23to2020-09-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-20-108972-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-108972-xbrl.zip
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MMBY/#%U0M #FX,N62A\"+XM'0JEZA(!9?^-B$[MF!C9L4M-6!L4-: \D)X]
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M#[4^S/\M0/7BNEJKCD=/BT<L3^/M-DM5SRKMP??1.X,</Z 84 #C,45'1$
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M+3%?.&LN:'1M[3UI<]K*LM^IXC_,XYYSRZYB$YO!<?S*QM@A7F/(XGQQ"6F
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MY?6Y/Q:W55,850SL6N6*B%<+A2-+\S"^P,SA5@O#ZTB@_6,Z5D8GHY.;LP;
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MWLR^[V"2OY:0I)T;?=0E+T])IWK=DXN#_L?KSHMD41M*'Q=;',0.A^BF'KE
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M;/(P<RH Q3]<*\G>M9!9^#EN:% .^NU@^D/&WGMI,.5K!!VT<*:7-<><]O$
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MR:Y@ X&E^02>JF<%M-FNP>!=!(ZX/T^>6$^<!O!\Z@2Y7NI&?40;'.6#SL?
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M X!.S<^*/Y7O4UH 2Q\7WB_X3&*?.$A,;O>.F<V!IM2/;, B?%C(P;C.7+@
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M?31[C^7=MM=QGLT$[[1YR5-6##,3N>V!7@ZW/ZRYBC<W+9G;H$7ELB0H'V(
M\I7:I+VAN<_*CED%4(T .Z^>L6[OM*C4)&8,->#HO,G'.F,GZ*R@/,B9]-=G
MFY,_LKWPKBB7_X:1C"XD>V"&+ZWQFHJ[-GJ5\6%91FNRHMF[&X1W2$4)W%BT
MC!M&R%J5"1$+,64_$%'/Y[ G&F6]9)>BBU"[<VP7U/'IN;(#O9"N1/*'O<T*
MH^1+J0]ZY&HC*(/F')^:XYIT>#X[1"LJ:*D@W!03-FFP,79(#O@ADWX(,\#V
M44+C;E++2R<]1NN4[,4TL.,P"W63]*+]Z!C@*4A8M*Q>DZ/5B2\KN^AY]_#6
MDA UE0(>CV+NS)ZQK\(#+TW'BI::U.ET@$L-6_(7A.=/XVQO2>3NN<:\)!AT
MC]G$J#@O-<#PT00%K,.%2!2:8SIR]*=>$'PLV%A;3> EY=IT!IX!8QKF\\AE
ME3W-UJ$S16H;43\VOO[VZ]E?0@/ZZP8UH!>P)\XCW%"3<ZZH$/F@-560*86;
M;YTZWH&Y#[VD!EO-4<M+$#O*)N/AWKN@J0V26KEF7**S&NDN>A!%^FK+91L>
M2T-=(/*2,[%=.BHTUDR*CGACH!M!TBFV.\,:&PQ'QDC?.3+/&%]MW:Q-;NI>
MG-)*M^G:I+8*1^9^G)P(^HQW.)Q,=6G4Y:!@ 4^FPYH61O!HBEIAGH V4:-E
M3;1'&DDR;Y S<EOJ:U(W/<]C'3):@*0BA#NKG^1E(ZCL/+NL&Q)%H"\4K)E\
M $6FT2W'HRC+?(BJ->DSM:;N,WM#R[6M/H@T\1YE$F_D<Q2N YXA>+^2E:*'
MB)D>0 4J%L&1(.]%X^\SD<D: \7PP"!C *7[N^;0ZN0,?KB[5U,F )BM.A?-
M5RT,.RN1]>LB;IT_XITYF\%USB<K/,:]O 9$6NL4#$3@A597-OL"@SP#$Q_V
MSGE?58L90.GYQ!3&#G7,OC++@]P2\MC'F2FL$YFL @_>'@PS];$$?7 9[0?U
MXD6NWEM_?^WH)[I_Q_Q$][_[B6Z[EO3N1@+A+[()WGEO<HF%L+\'=DF)7Z#.
MNT1"/6=K[ !X0")A$&^5<RH8@\-<P!Z?J^$^UX+4 ?UTOPR.I(I[:%FRT%BV
M!H]\-Q[YWA'>8Y$KH#L#">D,%T)_YH*VP4BI_,J]HM%YO2B6@?=B _9*XI=\
MWX>L2)77_>)>6TP*3K()1R<3V*>@9 9 &8=0"_@W>ZU.D)</$V/%C&&%TP_(
MAV_A"S]A"-M!*G&XZJ[;*F@6,WD)*DJ#%R:I9+&B4S#3&%WQ5\&FF' ML1YF
MRD5],*5;/^0^T^VH"+TT<",P%Y8K'.,(V6%Z.H[@.L>"GUT*\M;5/8Q@YET1
M?ND U7RKZVL#R)L^XLB>D#Y?RJ]2\A?IFCH(,"^;F7+9&8XZL"7(+^C'J'1)
M$M2/Y]WY7ASU55]1P*/:VR=RKKTFN.74!X".#E%.O?(.O?9Q0P6(.V'@Q&C>
M'P=G!QOH=20.1T3]0UQ5 7&EF28*3?H_U1N*<32B Z! H*FH[7(;W*^OLG/Q
MSEZ@S_5:+OX03NA8JE*J*7,)>C&54ZQ=>:;L_!R+DW3H+]HL'QFP^9V[REZJ
MY0VZ'IZX)177PVYFG*%<XOH3RI+(FCGO@D"^[4GZ-_,G!FY"%_"@)%XR^(C_
MBK])=^)93,4_9^];[=-NYL0^F::<E;+]<0=R\CX8-19I*$S=.30IX==V?M34
MPWVRHGR(LF:0L= >]@0OR^;@8P-3=ZC0D!&Y-KQWA6]J'M=M*5I8",)G[X$\
M$-M.Y"Z6-=?2*HT9A+/6>?&":@O] =.+':&@Y1 4AC.^4'M.(1^SV$Q(9DEX
M0T?"4"=0'J]0(C/O(8>BV-D>8 #E\>'76L"?<EP2@Z_<NX0$(3&?1C<!B6"^
M#&*F8E!JLO<H>?+JLFAJ?2FL4Y>+5Q /T5+93B_RK*1\"$0MSW/L%3Q+-6.H
M($2W-M_%5PAU@_1IN?3T1J#;W%5!_1"*PET5X#LIY1?[&X7V+M+_6LE^:O?,
M>/0"]A:)^*#U[:U<J_1X_R?JG=L3#JY3?*RBLP33P+'-^NV.1_!B!8NE.UW\
M/>9X!,R@V6)2T-8N&O2?-_,,^X6;,$W.&Q1O\D?)K#C\ !D\$_V+G%190+/3
MZVXN?C+,G$%%_ +V#N76Y1B!T0B5<ZC[C^?)] )^/"7$, ^:$P )089LO,I7
MW-7OBRF+LG]GS:Q>$1>J BOA\ZNLI8K-D2/;>['_Z7ZHQS $]5*67S2;:1#N
M[Y&HPTJL,#Z(%Q;''EHDA^!9<-'F%/ED4A_LQ(U0-Z!]DM6RK"G7D](R*7&4
MQEC-E#!HH-L$I[W*L<9U2SLL2 /A]*49SC]?*O0/Z.J,9Y+_G92Y"#G/9-MZ
MAML68Z!3PBIHJ*65&Q!O?/=CNJQP[9 [F0*,+GW(*/&I2^$AGQG^ V9KL2K/
MM>0;)[4H!I?U!0-Y#,YRHD=9E^Z1N6A1(*.^K3!LF!WIFQN0OT$UE<9@$VLI
M0-B+7?:[8$N2Q8$>T!Y< ):93BP79FPJ>5GAC)<DM%T<S)L'XU;'SQUTBBT7
MN:Q@$Q#;;ESWR3#N1C9.6RN>=^I#O8,!:YSDG>R>K_C*V]$G_>".^:0??/=)
MWW;%JKH1G_0;%W FYF.4L,.%0"D@994FN/%:JGF);$F^T$$;L3T+J8,([Y!5
MC43>LD%,DU.O!+'6#VX/Q<8)'V>8JS8*<@.DP=L6KE7*UAS*ADBQ-NEF%Y(.
MVXAQ:TE\D@5A[TH?H3;+XG,%C.OZ&A]'E-#DF+:)?\*0V,5:$1;LFVJ&$EA3
M]<S7?9&KS V#NWC[;X,O<4[K&SFG;XNN)'+TY(0P7CL>4C)LJ=8H,V8C'3?I
M01VV1YA/Y&(I0%^@W<W9EFR<1Z5049]B3K:M[8FJUI(E/]R*^(]:$RC@+>>@
MLOUTD-[0TLB>WT+XZGS"<W*JB ;%7+ H#+@VC';&@5_HE9>H%;BD/S<>\DOW
M?T@EQN<$5M'XTZK-%5XZH]\3JLWPCO?:WE"N+:QF2AWPZB /QJ6Q9"X($3EI
MG,XL'AG\A92/,+)8B&]M&I4@]F!H/4)BB1 0HIAXC*,NB)NN=?(*B?,KU#@Z
M$E>F^L<RAUW#:>DG%)2Q>XC3C*:*B[X Q4"YZ<@0W67B*+Y!O]2]R!8"09E2
M+GONRU+;4F5BZ])0>XGJGJMP>S#E;DK(Y8U(R.=P]LAEL*)+4W;-!\C)E&UV
MS_3 C+PIBS1T>I!E3/^PY=Y:,OO1'F_>V7_#I@@>PC.%]ZY]+JDR6@K^HT5#
MOR-CGGALZ6?3>KGF#GECWN2Z%V;8_JPH'1(YA$*V"J\OU:9X IYJ*GP^6/;B
M8W4I[H _+J&92G/-JM/V^-GVF@MVX1-=]^0-C3:HOH#\&X10^ 3U296GO:L&
MDY.KP+.TSS<;QR*XF\.[4GI';5,F./I2M' 5NU(X17@"'84^SS0$;Q5*_B%Y
MU?27_$/[,\T$NJJ3O6.Y+(AN "G2ZT649Q0R8N\60PLF*!6BN[#9S>E+07Z*
M2U'>E+Z4)3KK_9!5X.%32C:/AE!813*X6\8C61"M_$9WW!SS>'.F2B*-V-48
M\V11-J?J0^()GN5G"Q;U6DP'2B92'K:= ;J&@JJ;CC*)H=F:.H(:%8^9KF["
M,[.0$6*L$-6[[9T[( UH]%R4W4T3Z!*.KVH!'ZX:ACR([YP!M"@DL4YG!!Y)
MI+P!JVN9(S(JAF4D:5&!H2?"B93LF?C1=D<';%GK:\ !,4< YD.$:XY?H(.Z
MM2D<2!="))A83 Z/,KP&%1<FK%#'HB<M8KV8]731M[>N8)@LQ''M^$#!J]'%
MQ9Y[*=2PJC*ALS<5H7PWW!4F?/>X4-O/),M4Y"<:LO1Q7^F%=/O5JQW=D0_O
MF#ORX7=WY&U7XO]U0TH\R'P#X[E6<6<3"R\*,NGXGTVKY+[G%=5I\=EPJ,9B
M'JZ@YS0IB"[1LFY5MVZ*]IV@SY1O(UM@UHTK(;9L5C/%&TQA7F%1F&;&.C(H
M17B UVSC4/+J'';6S(1I4XQ!4:%15TH9Z4]GC@..J8P)5MCR^ 79!I<,[E*7
M0)<C>,(5CM:+B_J /*VD\)_0( /5SU7VV:3[,7P2+S]V:Q"0U=T/CK^3]%*^
M&)J\@GV,DMMEK0YUG,=V15P<M 3N*U9].2#M[AFU<]Q3="OJIVYG9*XT=7R?
M$(HSN% 4 X,AL!:.$'E B=X$2]RJN=3>4<]G<X, O[<!W_&?:)<:QF[<)Z<*
MBF:3_W0WJH/&)0U[[+H[375CSEFH>S.U9G@8V/EU/0[;O\GB\J]!ZQ6MDNN@
M@Y)Q<*2J$B[9)-@-(=^CMBS!+1K^XIF@L^&ZE/IYX (6,A$60Z+@-L5S!S ^
M"<Y[CE7F;>5BM^*IG*^:JF@O!"3A^L%$S1,&?IF?-))!.6?7(.(<^[YF_C$>
M_OCG))KKIJFOY(4+6(LURPE4335]3;_@EBQP!+TE1 ;%[LV65D#>MCES/\A7
MV"VQ@R#S()&ZM;]!!MM/W4X,WT*26<$UE*9/SNF<,V 12UD-- 8["01"GJ<A
M_:BF9#2T[RK\R#K?V17_?BJN^_\X.CY,#P\/DVB;.=>[<0ZW62FN*"KU7G9<
M"EEJ@+H-T2 7$WE)O,^[R8O%!&DV&#"%S_>).3#5,+_(ROE03,& .;BK;O:X
M6D 7$" &A J&*$)\T(.<"W%&XIV\)]J;H1G-FDD&E_:]5^_+?/UH/$*KLD')
M<.))W)Z@J*J'*AKOYL#W3-W$!X.@+8\M&N95#+I%W(JP)XX/#X^]8>OKJ W6
MT6!WY::7;J3: ]EHT%G]0F8&H[5K3[@#_K8R590&9S-BN%B FL8N@:1=@YA9
M,&&(+)/AVIO*,H'\0A%5"!2<I;G!,V$W56_$,=@2RH'"0&.C+)QA)D X%AE?
M4BZ=3.@ 27XS^=XT1NA9)B+S.BDQC&_(:;J<HDG7!8,&A)C0Q=,W,#KURC5J
MF(V)+'4^J=:[3*#C/+%8M2D)9\1B"T<(ZA/4$?(W5Q2\_"S3$M=?9BR!3D;0
M11;:OD-XSHC]QY3;UG </Y1U=O%IZQ#PC_:EB6"*+@1MLH=Q*$MJ5LR%GC9V
M=FT.I</U"6\&C26?F5PUOU\ER#L%!1/MDSV*C\R)^12FUY*I$M&G'-RC^]F]
MHX=[N<?VC4='#V?\V;Y37;:+*M31<C12<JF6N4/_,(I =I&8:S[%#L&7 >?4
M1GH8,7F%HYF\D4692\6W"<%CAHNH,)4.;PR'NV7"Q07<26BX<_R(F[;1#&6;
M4;[&@!TS%',^/304E,0?'0@M]R2CF=9<U41U8%Y^]"\KR>QPK<H=9GT'=(,7
MLD1#J3\1WF>R</U*?'P=FV2/=XJKDFBPNCQ4V@IQL=90UHM9PI/_:16.-)\2
M5*[6L,6.1WY)C%4RP>R43UF("3*!)7P58EJM&[*9_R2>",O0Y[_SE28;6_X3
MZU$P&Z#N3'?=2:<27,O 087S@P-%X<%4TYA&6SA)0MIV/'/[0[NJGSW**6J7
M>1_MXF.,)I!1%N^0#(:NFNCYE-6;W8>S0_]NOWJ\H__^ASOFO__AN__^MAMA
MW4UFXX*TSI!-_-E6=YR(L0UD_R Z)TW]CEVY-<D4. R>XC+/??$P3ELBO=M$
M(H6[<SRZ-G-6-$)^7VK$5S:[+%IVXHA_(L.^<5\H368J=83/J=-,<L3A\ZRB
MQO"_AEM(0NE#[("!#?$!)=WP,O8UJJ2B,TEY+,WDJJ$)3B_2@G4>A[XC9(60
M]TUHW@)WBAT0^VOFXLK,D@X$1C@&W ^$, DJ9="-)/[XV6H3_NACI^;6WR=?
MXJ2O;BA2ISO=!8CZ3A7F!6.+4#C"LLH[[AT4JU@L\AE^0NI%1[7^IGFQE"*)
M["U4,\B6(\2CKOR1"G[JOT#56G,ZIZKS<[DL8U@L\JPR^HH?IQN5^'".?GYP
MF!);/]6@SF?AV/D8#L$4. < MD:%+&/U4*B,*HOMTG%;.B(@(_,*]O4C2'0
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MJ*\XB5Q. ;MS ;\DY8_%*^4?8N2R*; F>T<W$2<&2(" F1:=6F'S%G&;>QR
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M=,;1<6)H@]--0![G+76^B5Y:_X=0+/OONK@4[&  R 5WB'YG>VG8CTO=/4!
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M#JD+E!%'J<&HW<)<M86'@NN:3A$\1_JR*ZJH& V^,7I02EX+O:VCJ @M0ZO
MZ/'(F"_!HWIC>V^ O;6_BOHVG]%3\_/-US;$TK3>2V-=Q5+J8*A.0>B*N2
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M=[12([35*A86(HVWQ"^G=?I>X="*WE@!>'1",=#M:B<2=%07(M0W!BT\M\_
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M@SA=011]-4H5?03I+[7/5]WB&$*',@3,Z!C(>SRDT/"^_]7ZBN.@>\/E^\H
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MMQ%]S&"R^79I7.493!9<NY:M\YHW9W#+;?GAJ(H3T,0P)>=L?*YE]CKX?K%
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M_[@JX>!!&2ZK)QA;:%(8J0VJ@76MHGS&XB!=-1*T\#F94R-C9D\0&=D0%,G
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MZ$[4-56KO2>Y4!LC=&U!1EP4N2,0+-'BBQU=@EFAB&.%-'AI]=**2D69YWO
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M$(I&G4CFC+ '4Y)4&!&F?+BKC <3W('MS6GR/CU&7H".\"'V,4KQ0=N;Z [
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MCZKG"LO#5U0]]J@U68*^[F:5R2+XQ<"D:TSS2!9;C'@)B6]0B\,R'S<VDA]
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M?]!>2Z+1PI/>L$\+E [3. $Q !?__+3(%&D\>32+RSI0+$KZMX(Y!"I&J_I
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M B,1K4/[0!D;7Y/\S;,<U]NOU^]-UW^(N[U:?.#I_0H%/'T(!1A'VJUSIXV
M:$[* H3OXW&1%>5+]";5"N9K_(U@\#@>>ZT$$OL9&M\LJKA#;?J,,1.S)E>J
M,I[I25I6M5:;;>ARG,7S2K-2TJ95]3(RJBIKT/V>9V2E9$7D49:2]@!30&<5
M!18=19HM+I[4"(RV6:?1II-QR.8"]@P46HG;GO^0*V3W-44.Q!6!"UX+C4XQ
M\KR<A-5F'E.Z6I=9.!A19!SCIK[=10GAO[Q\MA'%Z]-UWK(!TLX_BO)+M)O6
MG,"VAL; \Y<;3Z/9TL?6P P?R<ZC\?+A>/?_[> L\8>_P^S[/<^KX>WQ69'-
MIRB?,/L.EP2* =ZAY?M.PHT,I&"SHY:]IOF0><83\CQ+,/>Q1S6-K9=D^Y;M
M)PJ0->EQ[+K)NIWP0BI\EGT(WNMCSO++[3'"GS!X\#'-OT0?9O 7H8X!!:\H
MER_&A*V3.)?D(PJ?G !WQ.R?\5B)TZN@,HS)/!]+I<1$^Q#PSSRK-3Z#:5'5
MY.D%/</2O!>?:,R\*LR<*8 S2/0NYA&E#Y$Z@5D^%0\RB5/8@2FOADM(2 UI
M#X&01\EE!J"6($>:*6)+>(!E#'H)3%%E8*^RY^FD*##E$94C+[(E&L\T_JTH
M@6S)_YVB %.6N3A)W'0B;MX,'B7'D8!D3*H&*FU^)%!6JA3G)*JO,%W)^.&K
MK7WLP!.<\)M.*;H'@9@5) <Z31R9 31SDT*CE?/V>ZL+C21.@42NF*T]R) '
M&?(@0QYDR(,,629##H \PU3$DCTL?+9TY5N\&R).,*$7O].9;-GFA?&\Y<]
MF@Q^$2K&VQ)0Q?986%:8P4]G6L=?E&;LI3I!5H&^^3$\$P-YEO!!.C:Q'GD%
MYEHC?9ET@777:#P6,X@+Q7 APHP*'HWS;BK*/S)9YTR1P+8:R?I_4/(*TO(Q
MDA+FY7/$0S;(T1JT' Y2@(8=Z3OQO(8EU)*M;Q/DS](6LH0;[H1EVD]DR-4O
M(\LYW80F"8H>$C%)5AE5<%"RD BF,>7<U\QN*..+,CYJMJ%U2+'+,SED5I?J
M119YMG#25XC#%9Y/$50*^'JK0[.#YFXKL:WFN7MVOSQWSQX\=[>$K2U/9TIN
M,(GWG0(AEH/P:I3_W1&)LG*,8*6M3Z^Z''F%\G@N&77K8;7R\0D#3V%28E@M
M,T;;N4UUL24X-O>4,XRIO-!6F(JY2A6'_=[VB;)E79*!" ^-0>%):YVUA0("
M*T#:,UH$:2117$5C/A_%&<D4_6V2+;BB/46J3H';<%S"\9DUUJ>@3YZ<TOOD
M*7P]5J1B"62,U;#1+GRC2%*P(JH%J&;3:&"=%GN?MW=]3!,/L\*8WS%KF9CE
M0W$ZT4GEA22!)55IV^:1E)SLD3O2N70E>F4D^@S5D-KL'\46<VL#AX'(@BQ:
M+$K-NI[Q,\312-LQ$W/#DPTUM%VE877%8"]0%J@N7[1US1R?9.B9,6E3CCHL
M*DZ(!L(VH'Y./Y7'84)42#;#?D][\KLCMD4S7=8!K?&R9_RXJRZ72Y(2M\$6
MMWK[2H2 O[97ZYIL()TD2"J>4R+MT,KWED[W>W87$K]FFDW<SI)I2E-6L=1V
MNH ZW>7J[6OF3"9#:)T%=SR$2S7UZ9+JZ6#X@7$ L4G6@**1XLM(\\X&%L\Z
ML\YP LT%M12ZCG!?8/O8 T0<5H!WJ"@/6!!F/L*4I?P CH'9[ZE0\41*)3ON
M+3$]^&$F-0*:?IT[VZS3A2,LY3O(9+0!JS/1PH7Z0PZY\)#J8Y!.9_&"J..B
M8W&J7/2M'>N*Q'ZOP4$(+DJ#3]FZW^O"#$#<A!4O@.-JOI@DUJ,#7T),XC2K
MPJH5Y- &&<"3E6U.!*<B9 DG\;[E$_?0FQ$1*GJ9%O[8=-'Q7"@=*TO_/4\9
MLR:)IZ!$5P9B!YVD()+R.*L7[+\G]O"GS>'&QD8+FW46X''1?L^XH6D:G%;9
MG4>[<JHE6,]_VMP@+Z7+5S#!% ] ?*!_>KH!NQ \(T--TDE]&C69$LV_96M&
M()^XR'@\+N=JS>Y*QSN6\2))?W6?<_U>-KL3QA"R@;^-056M_ WV%3YQ$\$D
M355V[(!%Q"?&MT IJ(Y"H^_OF^VC8^0&)V4\12]OAI!%<14%U?'X^JKA)'4<
M!^O1MJ VL1]FZ"')==_$1LH!S:K2SU?V^9F(+O4545\$JB#NX 5#4X,<*A_
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M.XU]+$-1$]!CG*7BG2;NY/4HL!JR.1+7LH_>H$OP:PSO4$,=1Y0I&ZX3U+;
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M('"(EAP-O:O=H3:D*UI<^P'8S#L>:LW6:2R?DE%^Z-;B%H_4@NA3DX'L@X/
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M:2TR,#(P,#DR,U]L86(N>&UL4$L! A0#%     @ ^(@Y41%JK;%9!P  .ED
M !4              ( !H X  ')M=&DM,C R,# Y,C-?<')E+GAM;%!+ 0(4
M Q0    ( /B(.5$H+E%Y=1D  )J$   2              "  2P6  !T;3(P
M,S$W,#0M,5\X:RYH=&U02P$"% ,4    " #XB#E1JI9$F6V1  !U) , %@
M            @ '1+P  =&TR,#,Q-S T9#%?97@Q,"TQ+FAT;5!+ 0(4 Q0
M   ( /B(.5%/1ENCN3X  +MO 0 5              "  7+!  !T;3(P,S$W
M,#1D,5]E>#0M,2YH=&U02P$"% ,4    " #XB#E13\<\MF,^  "N: $ %0
M            @ %>  $ =&TR,#,Q-S T9#%?97@T+3(N:'1M4$L! A0#%
M  @ ^(@Y410SK5PM"@  ?20  !4              ( !]#X! '1M,C S,3<P
C-&0Q7V5X-2TQ+FAT;5!+!08     "  ( !("  !420$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
